Stephen Mok
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 13
- CAR-T cell therapy research 7
- Immunology top 2%
- Immunotherapy and Immune Responses 11
- Immune cells in cancer 8
- Immune Cell Function and Interaction 7
- Molecular Biology top 10%
- Melanoma and MAPK Pathways 8
-
- Cancer Mechanisms and Therapy 4
-
- Synthesis and biological activity 2
- Co-authors
- Antoni RibasRichard C. KoyaThomas G. GraeberLídia RobertGideon BollagBrian L. WestJingying XuLily Wu
- Cited by
- OncologyImmunologyMolecular Biology
- Journals
- Cancer Research (9 papers)Proceedings of the National Academy of Sciences (3 papers)Clinical Cancer Research (2 papers)
- Partner nations
- United StatesDenmarkSingapore
In The Last Decade
Stephen Mok
29 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 84
- Oncology 1.9k
- Immunology 1.5k
- Molecular Biology 873
- Cancer Research 145
- Pulmonary and Respiratory Medicine 248
Countries citing papers authored by Stephen Mok
This map shows the geographic impact of Stephen Mok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Mok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Mok more than expected).
Fields of papers citing papers by Stephen Mok
This network shows the impact of papers produced by Stephen Mok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Mok. The network helps show where Stephen Mok may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Stephen Mok, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 2 | |
| 2 | 2016 | 1 | |
| 3 | 2015 | 237 | |
| 4 | Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanomabreakdown → | 2015 | 435 |
| 5 | 2015 | 47 | |
| 6 | 2015 | 82 | |
| 7 | 2014 | 280 | |
| 8 | 2014 | 66 | |
| 9 | 2014 | 1 | |
| 10 | CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancerbreakdown → | 2013 | 467 |
| 11 | 2013 | 252 | |
| 12 | 2013 | 4 | |
| 13 | 2012 | 187 | |
| 14 | 2012 | 61 | |
| 15 | 2012 | 1 | |
| 16 | 2011 | 120 | |
| 17 | 2010 | 48 | |
| 18 | 2010 | 171 | |
| 19 | 2009 | 119 | |
| 20 | 2008 | 17 |
About Stephen Mok
Stephen Mok is a scholar working on Immunology, Oncology and Pathology and Forensic Medicine, having authored 29 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (11 papers), Melanoma and MAPK Pathways (8 papers), Immune cells in cancer (8 papers), CAR-T cell therapy research (7 papers), Immune Cell Function and Interaction (7 papers), Cancer Mechanisms and Therapy (4 papers) and Synthesis and biological activity (2 papers). The work is most often cited by research in Oncology (1.9k citations), Immunology (1.5k citations) and Molecular Biology (873 citations). Stephen Mok has collaborated with scholars based in United States, Denmark and Singapore. Frequent co-authors include Antoni Ribas, Richard C. Koya, Thomas G. Graeber, Lídia Robert, Gideon Bollag, Brian L. West, Jingying Xu, Lily Wu, Begoña Comı́n-Anduix and Jennifer Tsoi. Their work appears in journals such as Cancer Research, Proceedings of the National Academy of Sciences, Clinical Cancer Research, The Journal of Immunology and OncoImmunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.